Editas Medicine Inc Market Cap ($410.06 Million)
Market Cap & Net Worth: Editas Medicine Inc (EDIT)
Editas Medicine Inc market cap. Editas Medicine Inc (NASDAQ:EDIT) has a market capitalization of $410.06 Million ($410.06 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12927 globally and #3195 in its home market, demonstrating a 7.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Editas Medicine Inc's stock price $2.67 by its total outstanding shares 153580035 (153.58 Million).
Editas Medicine Inc Market Cap History (2016–2026)
Editas Medicine Inc market cap history from 2016 to 2026. Data shows change from $2.49 Billion to $410.06 Million (-16.36% CAGR). Check EDIT stock price for real-time trading data and today's change.
Index Memberships
Editas Medicine Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #353 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1279 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.02% | #195 of 263 |
Weight: Editas Medicine Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Editas Medicine Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Editas Medicine Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Editas Medicine Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
7.77x
Editas Medicine Inc's market cap is 7.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.49 Billion | $6.05 Million | -$97.18 Million | 411.80x | N/A |
| 2017 | $4.72 Billion | $13.73 Million | -$120.32 Million | 343.79x | N/A |
| 2018 | $3.49 Billion | $31.94 Million | -$109.95 Million | 109.40x | N/A |
| 2019 | $4.55 Billion | $20.53 Million | -$133.75 Million | 221.49x | N/A |
| 2020 | $10.77 Billion | $90.73 Million | -$109.41 Million | 118.67x | N/A |
| 2021 | $4.08 Billion | $25.54 Million | -$185.11 Million | 159.63x | N/A |
| 2022 | $1.36 Billion | $19.71 Million | -$204.35 Million | 69.11x | N/A |
| 2023 | $1.56 Billion | $78.12 Million | -$153.22 Million | 19.91x | N/A |
| 2024 | $195.05 Million | $32.31 Million | -$237.09 Million | 6.04x | N/A |
| 2025 | $314.84 Million | $40.52 Million | -$160.06 Million | 7.77x | N/A |
Competitor Companies of EDIT by Market Capitalization
Companies near Editas Medicine Inc in the global market cap rankings as of October 31, 2026. See how leveraged is Editas Medicine Inc's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Editas Medicine Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Editas Medicine Inc (2016–2026)
Market capitalization of Editas Medicine Inc from 2016 to today. Between 2016 and today, Editas Medicine Inc's market cap moved from $2.49 Billion to $ 410.06 Million, with a yearly change of -16.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $410.06 Million | +30.24% |
| 2025 | $314.84 Million | +61.42% |
| 2024 | $195.05 Million | -87.46% |
| 2023 | $1.56 Billion | +14.21% |
| 2022 | $1.36 Billion | -66.59% |
| 2021 | $4.08 Billion | -62.13% |
| 2020 | $10.77 Billion | +136.78% |
| 2019 | $4.55 Billion | +30.15% |
| 2018 | $3.49 Billion | -25.97% |
| 2017 | $4.72 Billion | +89.34% |
| 2016 | $2.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Editas Medicine Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $410.06 Million USD |
| MoneyControl | $410.06 Million USD |
| MarketWatch | $410.06 Million USD |
| marketcap.company | $410.06 Million USD |
| Reuters | $410.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more